SCHEMBL4698482

SCHEMBL4698482

O=C(NCc1ccco1)c1cc([N+](=O)[O-])ccc1Oc1cncc(Cl)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 5/20 0.55
SMN1; SMN2 Q16637 2/20 0.52
ALDH1A1 P00352 6/20 0.51
LMNA P02545 6/20 0.50
HTT P42858 2/20 0.50
HPGD P15428 2/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
GAA P10253 1/20 0.44
POLB P06746 2/20 0.43
MAPT P10636 1/20 0.43
NFKB1 P19838 1/20 0.43
RECQL P46063 1/20 0.43
BLM P54132 1/20 0.43
NFKB2 Q00653 1/20 0.43
CACNA1B Q00975 1/20 0.43
APBA1 Q02410 1/20 0.43
RELA Q04206 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4694703 0.85 HPGD (0.46) PPARGSMN1; SMN2ALDH1A1LMNAHPGD
SCHEMBL6564341 0.78 PPARG (0.58) PPARGALDH1A1MEN1KMT2AGAA
SCHEMBL31258878 0.77 PPARG (0.54) PPARGSMN1; SMN2ALDH1A1LMNAMEN1
SCHEMBL17627593 0.77 PPARG (0.54) PPARGSMN1; SMN2ALDH1A1LMNAMEN1
SCHEMBL4693343 0.76 SMN1; SMN2 (0.66) SMN1; SMN2ALDH1A1LMNAHTTHPGD
SCHEMBL4695752 0.76 PPARG (0.53) PPARGSMN1; SMN2ALDH1A1LMNAMEN1
SCHEMBL4697775 0.75 PPARG (0.76) PPARGALDH1A1MEN1KMT2A
SCHEMBL4694700 0.74 PPARG (0.61) PPARGSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL2031919 0.71 PDE7A (0.60) PPARGSMN1; SMN2ALDH1A1LMNAHPGD
SCHEMBL2030201 0.69 PPARG (0.47) PPARGALDH1A1LMNAHTTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1053227-B1 PPAR-GAMMA MODULATORS AMGEN INC (US) 2008-11-05 EP disclosed
US-7439242-B2 PPARγ modulators AMGEN INC. (US) 2008-10-21 US disclosed
US-6620827-B2 Peroxisome proliferator-activated receptors-gamma to control lipid metabolism ane obesity; antidiabetic, -inflammatory and -arthritic agents; non-insulin dependent diabetes; antilipemic and -cholesterol agents TULARIK INC. 2003-09-16 US disclosed
US-20030088103-A1 PPARgamma modulators TULARIK INC. (US) 2003-05-08 US disclosed
US-20010027200-A1 PPARgamma modulators TULARIK INC. 2001-10-04 US disclosed
US-6200995-B1 PYRIDYLOXYBENZENESULFONAMIDE DERIVATIVES; DIABETES, OBESITY TULARIK INC. 2001-03-13 US disclosed
EP-1053227-A1 PPAR-GAMMA MODULATORS TULARIK, INC. (US) 2000-11-22 EP disclosed
WO-1999038845-A1 PPAR-GAMMA MODULATORS TULARIK INC. (US) 1999-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030088103-A1 PPARgamma modulators PPARG, PPARA, PPARD PPARG 1/4885SMN1; SMN2 3973/4885ALDH1A1 1959/4885
US-20010027200-A1 PPARgamma modulators PPARG, PPARA, PPARD PPARG 1/4885SMN1; SMN2 3973/4885ALDH1A1 1959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.